4,481
edits
Changes
Volunteer Assignments and Opportunities (view source)
Revision as of 17:16, 21 May 2020
, 17:16, 21 May 2020no edit summary
Line 148:
Line 148:
|
|
|-
|-
−|Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms||'''''Overview'''''|| ||Example
+|Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms||'''''Overview'''''|| ||Jennelle Hodge (JH)
|
|
|
|
|-
|-
−|Example||'''''Overview'''''|| ||Example
+|Myeloid Neoplasms with Germline Predisposition||'''''Overview'''''|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Acute Myeloid Leukaemia with Germline CEBPA Mutation||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Myeloid Neoplasms with Germline DDX41 Mutation||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Myeloid Neoplasms with Germline RUNX1 Mutation||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Myeloid Neoplasms with Germline ANKRD26 Mutation||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Myeloid Neoplasms with Germline ETV6 Mutation||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Myeloid Neoplasms with Germline GATA2 Mutation||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities||'''''Overview'''''|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Acute Promyelocytic Leukemia (APL) with PML-RARA||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Acute Myeloid Leukemia (AML) with BCR-ABL1||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Acute Myeloid Leukemia (AML) with Mutated NPM1||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Acute Myeloid Leukemia (AML) with Mutated RUNX1||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Therapy-Related Myeloid Neoplasms||Disease|| ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Example|| || ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Example|| || ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Example|| || ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Example|| || ||JH
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Example|| || ||Example
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Example|| || ||Example
|
|
|
|
|-
|-
−|Example||Example|| ||Example
+|Example|| || ||Example
|
|
|
|